Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study

A Petzold, M J Eikelenboom, G Keir, D Grant, R H C Lazeron, C H Polman, B M J Uitdehaag, E J Thompson, G Giovannoni

Background: Neurofilament phosphoforms (Nf) are principal components of the axoskeleton released during axonal injury. Cerebrospinal fluid (CSF) levels of Nf phosphoforms might be useful surrogates for disability in multiple sclerosis (MS), aid in distinguishing clinical subtypes, and provide valuable prognostic information.

Method: Thirty four patients with MS were included in a three year follow up study along with 318 controls with other non-inflammatory neurological diseases. CSF levels of two Nf heavy chain (NfH) phosphoforms (NfH_SM35, NfH_SM34) were quantified at baseline and three year follow up using new ELISA techniques. Levels of NfH phosphoforms, the degree of phosphorylation (NfH_SM34:NfH_SM35 ratio), and changes in NfH levels between baseline and follow up (\Delta NfH) were related to the clinical phenotype (RR or SP/PP), to three clinical scales (Kurtzke’s EDSS, ambulation index (AI), and nine hole peg test (9HPT)), and to progression of disability.

Results: A significantly higher proportion (59%) of patients with SP/PPMS experienced an increase in NfH_SM35 levels between baseline and follow up compared with those with RRMS (14%, p < 0.05). CSF NfH_SM34 levels at baseline were higher in patients with SP/PP (11 pg/ml) compared with RR (7 pg/ml, p < 0.05) and NfH_SM35 levels were higher at follow up in SP/PP (129 pg/ml) compared with levels below assay sensitivity in RR (p < 0.05). NfH_SM35 correlated with the EDSS (r = 0.54, p < 0.01), the AI (r = 0.42, p < 0.05), and the 9HPT (r = 0.59, p < 0.01) at follow up.

Conclusion: The increase in NfH during the progressive phase of the disease together with the correlation of NfH_SM35 with all clinical scales at follow up suggests that cumulative axonal loss is responsible for sustained disability and that high NfH_SM35 levels are a poor prognostic sign.

A xonal pathology remains the “Achilles heel” of neurology. New insights from recent studies into the “axonal death cascade” in multiple sclerosis (MS) are that a high number of transected axons are already present in acute lesions (independent of demyelination), in patients with a short clinical course, and as a result of electrical activity in a hostile microenvironment. Axonal loss results in atrophy of the spinal cord, cerebellum, and cortex, all of which correlate with disability. In vivo quantification of axonal damage is a key tool for monitoring and understanding axonal pathology in complex diseases such as MS.

Neurofilaments (Nf) constitute a major component of the axoskeleton and are promising candidates for quantification of axonal damage because axonal transection results in disintegration of the distal axon membrane and Nf breakdown. Nf are released into the adjacent compartment—that is, the cerebrospinal fluid (CSF), where they can be measured.

This prospective study was stimulated by three questions:

- Can clinical subtypes of MS be distinguished on the basis of axonal damage (disease heterogeneity)?
- Does disability correlate with markers of axonal pathology?
- Can we predict loss of function by using biomarkers for axonal injury?

METHODS

The present study was approved by the local ethics committee, and written informed consent was obtained from all patients.

Patients

A total of 34 patients from a previously reported cohort with clinically definite MS were followed up after three years. A second CSF sample was available for 29 patients at the time of study. The patients with MS were classified as having relapsing remitting (RR, n = 11), or progressive (n = 23, SP/PP) disease. For the CSF analysis patients with primary (PP) and secondary (SP) progressive disease were pooled because of small numbers. However, we will also present a detailed subgroup analysis for classification of patients with RR (n = 10), SP (n = 16) and PP (n = 3) MS at baseline and at follow up. Nine patients had been started on treatment with interferon beta (IFN\(\beta\)) since recruitment in 1996. The control group consisted of 318 patients with other non-inflammatory neurological diseases (OND) from the National Hospital of Neurology and Neurosurgery, London, UK.

Restricted sample volume meant not all assays could be performed on each sample and the numbers available for each comparison are presented in table 1.

Clinical assessment

All patients were assessed within one week of each lumbar puncture using:

- 9HPT, nine hole PEG test; AI, ambulation index; BSP, brain specific proteins; CSF, cerebrospinal fluid; CTRL, control; EDSS, Expanded Disability Status Scale; ELISA, enzyme linked immunosorbent assay; IEF, isoelectric focusing; MS, multiple sclerosis; Nf, neurofilament; NfH, neurofilament heavy chain; NfH_SM34, NfH detected with SM34 antibody; NfH_SM35, NfH detected with SM35 antibody; NIL, neurofilament light chain; OND, other neurological diseases; PP, primary progressive; RR, relapsing remitting; SP, secondary progressive.
the Expanded Disability Status Scale (EDSS)\(^{22}\): ranging from 0 (normal) to 10 (death due to multiple sclerosis).

- an ambulation index (AI): ranging from 0 (no impairment) to 9 (restricted to wheelchair without independent transfer)

- the nine hole peg test (9HPT) measuring upper limb motor function.\(^{22}\)

The patients were classified as clinically advancing if they worsened on the EDSS scale by at least 1 point for an EDSS < 5.5 or at least 0.5 point for an EDSS > = 5.5.

### Assays

Samples of CSF were obtained by routine lumbar puncture. Aliquots of CSF were stored at -70 °C until assayed. Levels of NH phosphoforms were quantified using an in-house enzyme linked immunosorbent assay (ELISA) technique based on commercially available antibodies.\(^{21}\) This ELISA has been optimised for the capture antibody SMI35 which recognises a range of NH phosphoforms (170 kDa, pI 6.2 to 210 kDa, pI 5.1). In contrast, the capture antibody SMI34 only recognises extensively phosphorylated NH.\(^{24}\)

Unfortunately non-phosphorylated NH are susceptible to proteases,\(^{24-26}\) of which the CSF is a rich source. For this reason NH-\(^{SMI32}\) was not measured in the present study and a ratio of NH-\(^{SMI34}\) to NH-\(^{SMI35}\) was used to approximate the phosphorylation status (see below). Albumin in CSF and serum was determined by standard Laurell ''rocket'' electro-immunonassay.

### Data analysis

All statistical analyses and graphs were done using SAS software (version 8.2, SAS Institute, Inc, Cary, NC). Because of non-Gaussian distribution, median values and the 25–75% interquartile ranges (IQR) were calculated. Independent variables were compared using the non-parametric two sample exact Wilcoxon's rank sum test. If significance was based on small numbers the results were checked by the one tailed Fisher's exact test. The linear relationship between continuous variables was evaluated using the Spearman correlation coefficient. Multiple correlations were corrected using the Bonferroni method. Linear regression analysis was performed using the least squares method.

The change in NH levels between baseline and follow up was expressed as the difference:

\[ \Delta \text{NH} = \text{NH}_{\text{follow up}} - \text{NH}_{\text{baseline}}. \]

A positive number indicated an increase in the NH level at follow up. Because the interassay coefficient of variation for NH is 10.6%, only an increase of at least 11% was considered for further statistical analysis.\(^{21}\)

The phosphoform ratio is an estimate of the degree of phosphorylation and was expressed as a cross-sectional measure:

\[ \text{Ratio} = (\text{NH}^{\text{SMI34}}/\text{NH}^{\text{SMI35}}) \times 10. \]

A decrease in the ratio indicated an overall reduction in the level of phosphorylation. Values with zero denominator (or NH at baseline and follow up below assay sensitivity) could not be used for calculations and were excluded from this analysis.

### RESULTS

The demographic data at baseline are shown in table 1. As expected at baseline, EDSS, AI, and 9HPT were worse in patients with SP/PP disease than in those with RR disease. The CSF levels of NH-\(^{SMI35}\) were higher in patients with OND than in those with MS (p = 0.001, table 2). The CSF levels of NH-\(^{SMI34}\) were similar in both groups. No correlations were found between the NH phosphoforms or their ratio and age, disease duration, time from last relapse, relapse frequency, or the CSF albumin:serum albumin ratio (data not shown). The shortest relapse free time was three months at baseline in two patients. At follow up one patient with SP/PPMS experienced a superimposed relapse two weeks prior to the CSF sampling. There was no correlation with time from relapse in patients with SP/PPMS or RRMS at either sampling point.

### Axonal damage accumulates in SP/PP disease

A significant increase in NH-\(^{SMI35}\) from baseline to follow up was observed in a higher proportion of patients with SP/PPMS (13/22, 59%, p < 0.05) when compared with patients with RRMS (1/7, 14%, p > 0.05). At follow up the median CSF level of NH-\(^{SMI35}\) was higher for patients with SP/PP disease compared with patients with RR disease (see table 2, p < 0.05).

An increase of NH-\(^{SMI34}\) levels was observed in a similar proportion of patients with RR (5/7, 71%) and with SP disease (15/22, 68%). The CSF levels of NH-\(^{SMI35}\) were higher in patients with SP/PP than with RR disease (table 2, p < 0.05). The proportion of patients with RR (5/7, 71%) in whom NH-\(^{SMI34}\) increased was higher than the proportion with an increase in NH-\(^{SMI35}\) (1/7, 14%, p < 0.05). The NH-\(^{SMI34}\)/NH-\(^{SMI35}\) ratio decreased in 6/7 (86%) of patients with RR and 12/22 (55%) with SP disease. Neither of these comparisons reached statistical significance.

### Axonal injury correlates with disability

NH-\(^{SMI35}\) levels correlated with all three clinical scales at follow up (fig 2). The correlation was strongest for the 9HPT (r = 0.59, p = 0.001), followed by the EDSS (r = 0.54, p < 0.01), and the AI (r = 0.42, p < 0.05). The correlation with the AI was lost after Bonferroni correction. One outlier was observed for the 9HPT (fig 2C), but its exclusion did not change the significance of the correlation (r = 0.55, p < 0.01). The NH phosphoform ratio correlated with the EDSS...
Axonal injury and prognosis

The median CSF NfH SMI35 level (107 pg/ml) of patients with MS who progressed on the EDSS scale within three years showed a tendency to be higher compared with the median level of those who remained stable (38 pg/ml). However, this difference did not reach statistical significance for either the Total MS cohort or the clinical subtypes (table 3). However, this showed a tendency to be higher compared with the median level of those who remained stable (38 pg/ml). However, this difference did not reach statistical significance for either the Total MS cohort or the clinical subtypes (table 3). However, this showed a tendency to be higher compared with the median level of those who remained stable (38 pg/ml). However, this difference did not reach statistical significance for either the Total MS cohort or the clinical subtypes (table 3).

Subgroup analysis

Since there are differences in pathogenesis between SPMS and PPMS, particularly with reference to the degree of inflammation, CSF levels of NfH SMI35, NfH SMI34, and their ratio were also examined for all individual subgroups.

At baseline, there was a significant difference between these groups for NfH SMI35 ($F_{2,26} = 5.00, p<0.05$). The post hoc analysis revealed that CSF NfH SMI35 levels were higher in patients with PP disease (mean 26.6 pg/ml) compared with patients with SP (mean 10.19 pg/ml, $p<0.05$) and RR disease (mean 9.30 pg/ml, $p<0.05$). The post hoc analysis revealed that CSF NfH SMI35 levels were higher in patients with PP disease (mean 26.6 pg/ml) compared with patients with SP (mean 10.19 pg/ml, $p<0.05$) and RR disease (mean 9.30 pg/ml, $p<0.05$).

At follow up no such difference was found, probably due to the small numbers and therefore no post hoc analysis was performed.

DISCUSSION

The present study:

- provides evidence that accumulation of axonal damage as estimated by serial CSF NfH SMI35 levels predominates in SP/PPMS
- reveals a correlation between CSF levels of NfH SMI35 and the degree of disability on three clinical scales (EDSS, AI, 9HPT)
- failed to demonstrate that CSF NfH phosphoforms might predict the development of new disability in patients with MS.

We interpret these findings on the basis of the epidemiologically supported hypothesis that axonal damage is a gradual cumulative process during the course of the disease and that loss of neurological function is a direct consequence of axonal injury.

Firstly, NfH SMI35 levels increased from baseline to the three year follow up sampling in about half of our patients with
Accumulated axonal damage in MS

A significantly higher proportion of these patients had SP/PP than RR disease. Additionally, the median NfH SMI35 level was significantly higher in SP/PP rather than in RR disease. The marked increase of NfH SMI34 levels suggests that NfH phosphorylation may increase with disease duration. This interpretation contrasts with the consistent immunocytochemical observation that injured and demyelinated axons stain for non-phosphorylated NfH (NfH SMI32). However, none of these studies presented quantitative data comparing the number of axons staining for phosphorylated versus non-phosphorylated NfH. A further complicating factor is that proteolytic enzyme activity is a prominent feature of the MS plaque and potentially affects the levels, particularly of non-phosphorylated NfH, which is susceptible to proteolysis. To address this question we are currently analysing the quantitative distribution of NfH phosphoforms (NfH SMI32, NfH SMI34, and NfH SMI35) in microdissected brain tissue homogenates from a previously published cohort.

An increase in NfH phosphorylation supports our finding and can be explained by targeted phosphorylation of the KSP repeats of the NFH and NF-M tail domains by ERK1/2. Fibrin upregulates ERK1/2 and has shown to be deposited on injured axons. Additionally the mitogen activated protein (MAP) kinases SAPKs and ERK1/2 are activated by glutamate which in turn leads to Ca influx, slowing of axonal Nf transport, and increased Nf phosphorylation.

Glutamate toxicity is an important pathological feature in MS, metabotropic glutamate receptor group I alpha is upregulated on axons in MS and experimental treatment with the AMPA/kainate antagonist NBOX reduces axonal damage in experimental autoimmune encephalomyelitis. The present CSF results are also consistent with the postmortem observation that axonal damage increases with time in SP/PPMS patients, with additional support from brain imaging and epidemiological studies.
Secondly, we found a correlation between CSF NfH^{SMI35} and three clinical scales. This finding indirectly confirms two previous reports on a different NF subunit (the 68 kDa light chain, NFL). Lycke et al. reported CSF NFL correlated with the EDSS at baseline (r = 0.27) and follow up (r = 0.34) in patients with RRMS. Semra et al. found CSF NFL correlated with the EDSS (r = 0.41) in patients progressive MS. However, no such correlations were found at baseline in our original study, the present follow up cohort, or a recent study on patients with RRMS and SPMS. Because clinically, some of our patients with SP/PP disease improved a degree of disability at baseline, it is likely that conduction block and demyelination which are, in contrast to axonal loss, reversible, contributed to the deficit.

Thirdly, a tendency for higher median CSF NfH^{SMI35} and NfH^{BASELINE} levels were observed in those patients with MS who progressed clinically on the EDSS scale. This was most marked for patients with RR disease and suggests that axonal damage during the course of MS is a poor prognostic feature. However, the study failed to show statistical difference. The high positive predictive value and sensitivity suggest that this might be due to the small sample size. It is important to note that axonal loss is not the dominant pathological feature in MS compared with other neurological diseases. Nevertheless, the demonstrated slow accumulation of axonal loss seems a logical explanation for the development of sustained disability in the progressive course of the disease.

When interpreting the present data one needs to consider that the patient group is population based and the numbers small. Clinically, there was no significant change in the EDSS of the patients with SP/PPMS within three years. This represents a benign course compared with the more rapid progression observed in other cohorts of patients selected from hospital populations. Additionally, the low median CSF NfH^{SMI35} level of the RRMS cohort at follow up would suggest that these patients might have a benign disease course. The results must be interpreted with caution and will need to be cross-validated in other longitudinal studies with different cohorts of patients.

Taking all these observations together, the results of the present study are in accordance with the current concept of progressive axonal degeneration in MS which is based on evidence from animal, human postmortem, magnetic resonance spectroscopy, magnetic resonance imaging, and epidemiological studies.

In conclusion, the findings of our prospective three year study support the idea that CSF NF phosphoforms might be valuable surrogate markers which have the potential to be used as new secondary outcome measures in trials of MS treatment.

Table 3: CSF levels and ratio of NfH phosphoforms for clinically progressive versus stable patients at baseline. Values are median (interquartile range)

<table>
<thead>
<tr>
<th></th>
<th>MS (all patients)</th>
<th>RR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stable</td>
<td>Progressive</td>
</tr>
<tr>
<td>Number</td>
<td>19</td>
<td>15</td>
</tr>
<tr>
<td>NfH^{SMI35} (ng/ml)</td>
<td>38 (17–155)</td>
<td>107 (49–163)</td>
</tr>
<tr>
<td>Ratio</td>
<td>11 (5–13)</td>
<td>8 (5–14)</td>
</tr>
</tbody>
</table>

See table 2 for abbreviations.

REFERENCES


